DMK Pharmaceuticals Corporation (DMKPQ)
OTCMKTS
· Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Oct 30, 2024, 4:00 PM EDT
DMK Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | 2017 - 2013 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '23 Sep 30, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | 2017 - 2013 |
| Revenue | 3.62 | 4.76 | 2.21 | 2.78 | 22.11 | 15.09 | Upgrade
|
| Revenue Growth (YoY) | 150.33% | 115.34% | -20.45% | -87.44% | 46.58% | 15.40% | Upgrade
|
| Cost of Revenue | 4.97 | 6.19 | 6.87 | 6.33 | 15.8 | 9.8 | Upgrade
|
| Gross Profit | -1.35 | -1.43 | -4.66 | -3.55 | 6.31 | 5.29 | Upgrade
|
| Selling, General & Admin | 12.97 | 13.25 | 16.14 | 20.09 | 25.29 | 25.95 | Upgrade
|
| Research & Development | 2.97 | 10.38 | 11.26 | 8.04 | 10.38 | 18.79 | Upgrade
|
| Operating Expenses | 15.93 | 23.63 | 27.41 | 28.13 | 35.66 | 44.74 | Upgrade
|
| Operating Income | -17.28 | -25.06 | -32.07 | -31.68 | -29.35 | -39.45 | Upgrade
|
| Interest Expense | -0.14 | - | -0.01 | -0 | -0.12 | -0.16 | Upgrade
|
| Interest & Investment Income | 0.02 | 0.04 | - | - | 0.18 | 0.25 | Upgrade
|
| Other Non Operating Income (Expenses) | 3.32 | 0.09 | -7.53 | 0.5 | 1.79 | - | Upgrade
|
| EBT Excluding Unusual Items | -14.07 | -24.92 | -39.61 | -31.18 | -27.5 | -39.37 | Upgrade
|
| Asset Writedown | -0.12 | - | - | -4.66 | - | -0.01 | Upgrade
|
| Other Unusual Items | 0.38 | -1.87 | 5.01 | - | - | - | Upgrade
|
| Pretax Income | -21.16 | -26.2 | -34.6 | -35.84 | -27.5 | -39.38 | Upgrade
|
| Income Tax Expense | 0 | 0 | 0 | 0 | 0.01 | -0.37 | Upgrade
|
| Earnings From Continuing Operations | -21.16 | -26.2 | -34.6 | -35.85 | -27.51 | -39.01 | Upgrade
|
| Earnings From Discontinued Operations | -1.08 | -0.28 | -11.23 | -13.54 | - | - | Upgrade
|
| Net Income | -22.23 | -26.48 | -45.83 | -49.39 | -27.51 | -39.01 | Upgrade
|
| Preferred Dividends & Other Adjustments | 0.17 | - | - | - | - | - | Upgrade
|
| Net Income to Common | -22.41 | -26.48 | -45.83 | -49.39 | -27.51 | -39.01 | Upgrade
|
| Shares Outstanding (Basic) | 4 | 2 | 2 | 1 | 1 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 4 | 2 | 2 | 1 | 1 | 1 | Upgrade
|
| Shares Change (YoY) | 63.90% | 3.95% | 85.84% | 45.63% | 36.28% | 37.87% | Upgrade
|
| EPS (Basic) | -6.39 | -12.37 | -22.25 | -44.57 | -36.16 | -69.86 | Upgrade
|
| EPS (Diluted) | -6.39 | -12.37 | -22.25 | -44.57 | -36.16 | -69.86 | Upgrade
|
| Free Cash Flow | -9.47 | -26.59 | -38.94 | -21.07 | -22.75 | -36.19 | Upgrade
|
| Free Cash Flow Per Share | -2.70 | -12.42 | -18.91 | -19.01 | -29.90 | -64.82 | Upgrade
|
| Gross Margin | -37.30% | -30.10% | -211.14% | -127.87% | 28.55% | 35.06% | Upgrade
|
| Operating Margin | -477.45% | -526.88% | -1451.97% | -1140.96% | -132.72% | -261.51% | Upgrade
|
| Profit Margin | -618.98% | -556.72% | -2074.91% | -1778.84% | -124.41% | -258.55% | Upgrade
|
| Free Cash Flow Margin | -261.75% | -559.05% | -1763.05% | -758.70% | -102.89% | -239.90% | Upgrade
|
| EBITDA | -16.65 | -23.58 | -30.63 | -29.35 | -26.61 | -36.35 | Upgrade
|
| EBITDA Margin | - | - | - | - | -120.31% | -240.97% | Upgrade
|
| D&A For EBITDA | 0.64 | 1.48 | 1.44 | 2.33 | 2.74 | 3.1 | Upgrade
|
| EBIT | -17.28 | -25.06 | -32.07 | -31.68 | -29.35 | -39.45 | Upgrade
|
| EBIT Margin | - | - | - | - | -132.72% | -261.51% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.